The Accula system will accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care
Thermo Fisher Scientific yesterday introduced a new and innovative Accula SARS-CoV-2 Test that delivers gold-standard Reverse Transcription Polymerase Chain Reaction (RT-PCR) detection of SARS-CoV-2 in a point-of-care format.
RT-PCR testing is streamlined from start to finish using a fully integrated, single-use microfluidic test cassette and the reusable, palm-sized Accula Dock. The test uses nasal swab samples and provides reliable and qualitative results in approximately 30 minutes. The Accula SARS-CoV-2 Test is enabled by proprietary PCR technology that allows for reduced absolute temperatures and reduced temperature differentials — resulting in rapid exponential amplification while reducing overall thermocycling times.
“Since the start of the pandemic, Thermo Fisher has acted quickly to provide support to the scientists and healthcare professionals at the frontlines of combating COVID-19,” said Amit Chopra, Managing Director – India and South Asia, Thermo Fisher Scientific.
He added, “Thermo Fisher’s new testing platform combines the accuracy of RT-PCR with the simplicity, convenience and procedural familiarity of traditional rapid immunoassays. The Accula SARS-CoV-2 test is natural extension to our existing offerings and will significantly help to meet the continuing demands for rapid and reliable COVID-19 testing in India.”
The test has received Emergency Use Authorisation (EUA) from the United States Food and Drug Administration (FDA) for the detection of SARS-CoV-2 in Clinical Laboratory Improvement Amendments (CLIA)–waived environments.
“The rapid Accula point-of-care test will open new avenues of personal and public testing without compromising on accuracy. The introduction of the test in India is a demonstration of the impact our solutions have on human health during the pandemic, and far beyond,” Chopra further said.
- Advertisement -